Company news
Jiangsu Lianhuan Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Report for Q3 2026
October 28, 2026
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Resolutions of the 29th Extraordinary Meeting of the 9th Board of Directors
October 28, 2026
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Re-appointment of Accounting Firm
October 28, 2026
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Borrowing from a Related Party by a Controlled Sub-subsidiary and Related Party Transaction
October 28, 2026
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization
October 20, 2026
(600513)"Jiangsu Lianhuan Pharmaceutical Co., Ltd."Announcement on Receipt of Approval Notice for Drug Supplementary Application
October 20, 2026
Announcement on Outline of the 2026 Semi-annual Performance Briefing
September 28, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 22, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 17, 2026
Semi-annual Report for 2026
August 28, 2026
Announcement on the Addition of a Related Party Not Under Common Control and Increase of the Estimated Amount of Routine Related Party Transactions for 2026
August 24, 2026
Announcement on Resolutions of the 26th Extraordinary Meeting of the 9th Board of Directors
August 11, 2026
Announcement on Obtaining Drug Registration Certificate
August 7, 2026
Announcement on the Proposed Selection of the Company and Controlled Subsidiary in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
Investor Relations Activity Record Form
July 27, 2026
Announcement on the Company's Receipt of the Approval for Marketing of a Chemical API
July 22, 2026
Announcement on Execution of the "Project Entry Agreement" by the Company and Its Controlled Subsidiary and the Progress of External Investment
July 21, 2026
Announcement on Acquisition of Drug Registration Certificate by a Controlled Subsidiary
July 16, 2026
Semi-annual Performance Forecast for 2026
July 14, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 13, 2026
Announcement on Adjustment of Members of the Special Committees
June 30, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 29, 2026
Announcement on Resignation of Deputy General Manager
June 22, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
June 12, 2026
Announcement on Receiving Results of GMP Compliance Inspection Concerning Drugs
May 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 28, 2026
Announcement on Resignation of Independent Director Upon Expiration of Term of Office
May 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 20, 2026
Investor Relations Activity Record Form
May 18, 2026
Announcement on the Holding Subsidiary Obtaining the Approval Notice for Drug Supplementary Application
May 11, 2026
Announcement on Unblinding Results of the Phase III Monotherapy Clinical Trial of the Company's Class 1 New Drug LH-1801 Tablets Combined with Metformin
May 7, 2026
Announcement on Unblinding Results of the Phase III Clinical Trial of Company's Class 1 New Drug LH-1801 Tablets Combined with Metformin
April 29, 2026
Announcement on the Signing of the "Project Entry Contract for the Science and Innovation Center" by with Yangzhou High-tech Industrial Development Zone
April 27, 2026
Announcement on the Execution of Daily Related Party Transactions in 2025 and the Estimated Daily Related Party Transactions in 2026
April 20, 2026
Announcement on Abnormal Fluctuations in Stock Trading
April 8, 2026
Announcement on Obtaining Drug Registration Certificate
March 16, 2026
Announcement on Obtaining a Drug Registration Certificate from the Republic of Ghana
February 9, 2026
Announcement on Increasing Capital to Wholly-owned Subsidiary
February 6, 2026
Announcement on Progress in Asset Purchase by Wholly-owned Subsidiary and Related Party Transactions
January 29, 2026
Announcement on Resolutions of the 21st Extraordinary Meeting of the 9th Board of Directors
January 23, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
January 22, 2026
Announcement on Obtaining Notice of Approval for Clinical Trials of Class 2 Improved New Drug
January 16, 2026
Announcement on Obtaining an Approval for Registration of Issued Science and Technology Innovation Bonds
January 14, 2026
Announcement on Holding Subsidiary Obtaining Drug Registration Certificate
December 26, 2025
Announcement on Active Pharmaceutical Ingredient Levonorgestrel Passing the World Health Organization Prequalification
December 23, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
December 22, 2025
Announcement on Convening the Q3 2025 Performance Briefing
December 11, 2025
Announcement on Holding Subsidiary Passing Generic Drug Consistency Evaluation
December 4, 2025
Announcement on Adding Extraordinary Proposal to the 4th Extraordinary General Meeting in 2025
December 3, 2025
Announcement on Amending the Articles of Association, and Formulating and Revising Some Governance Systems
December 2, 2025